Presentation

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Presenter: Brian A. Ference

May 07, 2018

REGISTER for free or LOG IN to view this content

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Clinical Cardiology

Clinical Pharma

Lipids

Presentation

EAS 2018

Lipoprotein a

Up Next

Presentation

12-Month Results From First-in-Human Randomized Study of Ranger DCB for Femoropopliteal Treatment

May 08, 2018

More slides +

Presentation

Causes and Associated Costs of 30-Day Readmission of TAVR vs SAVR in the US

May 11, 2018

Presentation

Trends in P2Y12 Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After PCI, 2008-2016

May 21, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.